Novartis, Amneal Settle Exelon Patch Infringement Fight
Novartis Pharmaceuticals Corp. and Amneal Pharmaceuticals Inc. have settled a suit accusing generic drugmaker Amneal of infringing two patents when applying to sell its own version of the dementia-treatment patch, Exelon,...To view the full article, register now.
Already a subscriber? Click here to view full article